For patients facing rare and often debilitating neurological disorders, specialized treatments like Nulibry, Yorvipath, and Ingrezza offer potential relief and hope. These FDA-approved medications target …

Valbenazine (Ingrezza, Neurocrine Biosciences), approved by the FDA in 2017, is the first medication indicated for the treatment of adults with TD. 9 Until now, there has been no well-studied treatment …

Learn how always once-daily INGREZZA® (valbenazine) capsules can be used to treat tardive dyskinesia (TD). See PI, including Boxed Warning, and Med Guide.

Jan 21, 2026 · Ingrezza (valbenazine) is used to treat tardive dyskinesia (TD) and chorea associated with Huntington's disease. Ingrezza uses, side effects, doses, and more.

INGREZZA ® (valbenazine) capsules and INGREZZA ® SPRINKLE (valbenazine) capsules are indicated in adults for the treatment of tardive dyskinesia and for the treatment of chorea associated …

Oct 1, 2025 · VMAT2 inhibitors, including INGREZZA and INGREZZA SPRINKLE, can increase the risk of depression and suicidal thoughts and behavior in patients with Huntington’s disease. Anyone …

Nulibry and Yorvipath are typically used in pediatric or rare disease contexts, while Ingrezza sees broader use across adult populations managing mental health conditions. How These Treatments …

Get information on how to take INGREZZA®, formulations and dosing options for tardive dyskinesia. See PI, including Boxed Warning, and Med Guide.

Understand how INGREZZA® may work to treat tardive dyskinesia by reducing uncontrollable movements. See PI, including Boxed Warning, and Med Guide.

This guide explores essential information about nulibry, yorvipath, and ingrezza treatment, three therapies used in managing rare and specific medical conditions While each medicine targets …